Exosens Shares Bounce Back to €58.20 After a Weekly Decline of 9.56%
Exosens shares recover in the mid-afternoon to €58.20, after a challenging week that saw the stock lose nearly 10%. The specialist in night vision and imaging technologies for defense benefits from a positive session in Paris, with the SBF 120 up by 0.85%. The increase follows the announcement of the consolidation of the group's brands under a single banner.
Technical Rebound from the Lower Bollinger Band After Ten Days of Decline
Exosens shares are trading at the lower end of the Bollinger Band (8%), close to the lower boundary set at €57.21. The price also remains near the support level identified at €56.45, which was tested at the beginning of the week. The RSI at 34 has just exited the oversold zone, indicating seller exhaustion after the weekly decline of 9.56%. Today's rebound is still contained below the 20-day moving average (€63.41), which is 8.22% above the current price. Over a longer horizon, the stock maintains a gain of 72.19% over one year and remains 13.41% above its 200-day moving average (€51.32), signaling that the underlying trend is not compromised by the recent correction.
Tight Valuation Approaching the General Meeting on May 22
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Exosens published at the end of April a quarterly revenue increase of 19.7% to €122.6 million, driven by demand in night vision and digital imaging for defense, as detailed in the quarterly publication. The adjusted gross margin improved by 20.1%, despite a decline in the margin rate in Detection & Imaging. Based on the consensus of eight analysts, the stock is trading at about 30.9 times earnings for the current fiscal year and 26.1 times those of the next fiscal year, compared to an 'Industrials' sector average of 18.1 times. The expected growth in earnings per share is 18.4% from one fiscal year to the next. The financial calendar schedules the annual general meeting for May 22, followed by the semi-annual results on July 28, 2026. The support at €56.45 remains the short-term reference level.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
